GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (NYSE:DVA) » Definitions » Cash And Cash Equivalents

DVA (DaVita) Cash And Cash Equivalents : $795 Mil (As of Dec. 2024)


View and export this data going back to 1995. Start your Free Trial

What is DaVita Cash And Cash Equivalents?

DaVita's quarterly cash and cash equivalents increased from Jun. 2024 ($416.49 Mil) to Sep. 2024 ($1,070.78 Mil) but then stayed the same from Sep. 2024 ($1,070.78 Mil) to Dec. 2024 ($794.93 Mil).

DaVita's annual cash and cash equivalents increased from Dec. 2022 ($244.09 Mil) to Dec. 2023 ($380.06 Mil) and increased from Dec. 2023 ($380.06 Mil) to Dec. 2024 ($794.93 Mil).


DaVita Cash And Cash Equivalents Historical Data

The historical data trend for DaVita's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DaVita Cash And Cash Equivalents Chart

DaVita Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 324.96 461.90 244.09 380.06 794.93

DaVita Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 380.06 345.13 416.49 1,070.78 794.93

DaVita Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


DaVita  (NYSE:DVA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


DaVita Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of DaVita's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


DaVita Business Description

Traded in Other Exchanges
Address
2000 16th Street, Denver, CO, USA, 80202
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.
Executives
Berkshire Hathaway Inc 10 percent owner 3555 FARNAM STREET, OMAHA NE 68131
Javier Rodriguez officer: Chief Executive Officer, DKC 601 HAWAII ST., EL SEGUNDO CA 90245
Joel Ackerman officer: Chief Financial Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Michael David Staffieri officer: Chief Operating Officer, DKC 2000 16TH STREET, DENVER CO 80202
Kathleen Alyce Waters officer: Chief Legal Officer C/O DAVITA INC., 2000 16TH STREET, DENVER CO 80202
Barbara J Desoer director CITIGROUP INC., 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
James O Hearty officer: Chief Compliance Officer 2000 16TH STREET, DENVER CO 80202
Christopher Michael Berry officer: Chief Accounting Officer C/O SONDER HOLDINGS INC., 101 15TH ST., SAN FRANCISCO CA 94103
Wendy Lee Schoppert director 6105 TRENTON LANE NORTH, MINNEAPOLIS MN 55442
Phyllis R Yale director
Charles Berg director, officer: Executive Chair, DMG 48 MONROE TURNPIKE, TRUMBULL CT 06611
John M Nehra director 1119 ST PAUL ST, BALTIMORE MD 21202
Adam H Schechter director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jason M. Hollar director 3333 BEVERLY ROAD, HOFFMAN ESTATES IL 60179
Paula A Price director ONE CVS DRIVE, WOONSOCKET RI 02895